Magnetic Resonance Tumor Regression Grade(mrTRG) as a Novel Biomarker to Stratify Management of Good and Poor Responders to Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial

Faculty of Medical Sciences0 个研究点开始时间: 待定最近更新: 2024年8月20日

适应症

试验速览

暂无简介。

•1. Male and female patients aged 18 years and older
•2. Have a biopsy-confirmed adenocarcinoma 0-15cm from the anal verge (on MRI or rigid sigmoidoscopy).
•3. Have locally Advanced Rectal Carcinoma diagnosed by MRI (mrCRM unsafe or >mrT3c [>5mm beyond muscularis propria] or mrEMVI positive disease)
•4. Be deemed to require chemoradiotherapy.
•5. Scheduled to receive 45Gy - 55Gy long course radiotherapy.
•6. Have provided written informed consent to participate in the study.

•1. Have metastatic disease (including resectable liver metastases).
•2. Are contraindicated for MRI e.g. non-MR compatible hip prosthesis, cardiac pacemaker.
•3. Are scheduled to receive less than 45Gy or more than 55Gy long course radiotherapy.
•4. Are contraindicated for chemoradiotherapy (CRT)
•5. Hypersensitivity or contraindication to the drug(s) associated with the planned choice of systemic chemotherapy (CAPOX, FOLFOX or single agent 5-FU or capecitabine) as stated in the SmPC for each of the drugs.
•6. Are receiving or planned to receive treatment outside of that stipulated by the protocol, such as an alternative cytotoxic or investigational drug.
•7. Are pregnant, breastfeeding or unable / unwilling to comply with pregnancy prevention guidelines.
•8. Any other malignant disease within the preceding 5 years with the exception of non- melanomatous skin cancer, carcinoma in situ and early stage disease with <5% recurrence risk

发起方